USS Valeda (SP-592)

LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data

Retrieved on: 
Wednesday, March 15, 2023
General Health, Medical Devices, Health, Optical, Clinical Trials, Arm, PBM, Stanford University, Duke University, USS Valeda (SP-592), GA, European, Visual acuity, OCT, Ophthalmology, Patient, Master of Science, MBA, Disease, AMD, Safety, Paratriathlon, Geographic atrophy, Letter, HIV disease progression rates, Pharmaceutical industry, Medical device, MD

LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data from its LIGHTSITE III, multi-center clinical trial which demonstrated sustained vision improvement in dry Age-Related Macular Degeneration (AMD) subjects treated with the Valeda® Light Delivery System.

Key Points: 
  • LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data from its LIGHTSITE III, multi-center clinical trial which demonstrated sustained vision improvement in dry Age-Related Macular Degeneration (AMD) subjects treated with the Valeda® Light Delivery System.
  • LIGHTSITE III, a prospective, double-masked, randomized, multi-center clinical trial, was conducted at ten leading US retinal centers and enrolled 100 subjects with early to intermediate dry AMD.
  • The last treatment was administered at 21 months and the last follow-up visit was at 24 months.
  • At 24 months there were minimal safety risks and high patient compliance; 80% of the patients completed the trial.

LumiThera Announces Fast Company Honors AdaptDx Pro As An Innovation and Design Award Winner

Retrieved on: 
Thursday, September 15, 2022
Electronics, Sale, FDA, USS Valeda (SP-592), Prevalence, Food, PBM, CE marking, Severe cognitive impairment, EU, Patient, CEO, Technology, Pathology, Architecture, Fast Company, Diagnosis, Cooking, Ageing, AMD, Marketing, Union, Fast, Disease, Pharmaceutical industry, Medical device

"We are honored to be recognized by the Fast Company 2022 Innovation by Design Awards for the AdaptDx Pro," stated Clark E. Tedford, Ph.D., President and CEO, LumiThera, Inc. "This confirms our excitement for the innovative design of the AdaptDx Pro and further validates our assessment of its importance in the early diagnosis of dry AMD."

Key Points: 
  • "We are honored to be recognized by the Fast Company 2022 Innovation by Design Awards for the AdaptDx Pro," stated Clark E. Tedford, Ph.D., President and CEO, LumiThera, Inc. "This confirms our excitement for the innovative design of the AdaptDx Pro and further validates our assessment of its importance in the early diagnosis of dry AMD."
  • LumiThera purchased the AdaptDx Pro and the other MacuLogix assets in July of 2022.
  • The wearable AdaptDx Pro dark adaptometer is the leader in early diagnosis of dry Age-related Macular Degeneration (AMD).
  • Fast Company is a monthly American business magazine published in print and online that focuses on technology, business, and design.

LumiThera Announces Fast Company Honors AdaptDx Pro As An Innovation and Design Award Winner

Retrieved on: 
Thursday, September 15, 2022
Electronics, Sale, FDA, USS Valeda (SP-592), Prevalence, Food, PBM, CE marking, Severe cognitive impairment, EU, Patient, CEO, Technology, Pathology, Architecture, Fast Company, Diagnosis, Cooking, Ageing, AMD, Marketing, Union, Fast, Disease, Pharmaceutical industry, Medical device

"We are honored to be recognized by the Fast Company 2022 Innovation by Design Awards for the AdaptDx Pro," stated Clark E. Tedford, Ph.D., President and CEO, LumiThera, Inc. "This confirms our excitement for the innovative design of the AdaptDx Pro and further validates our assessment of its importance in the early diagnosis of dry AMD."

Key Points: 
  • "We are honored to be recognized by the Fast Company 2022 Innovation by Design Awards for the AdaptDx Pro," stated Clark E. Tedford, Ph.D., President and CEO, LumiThera, Inc. "This confirms our excitement for the innovative design of the AdaptDx Pro and further validates our assessment of its importance in the early diagnosis of dry AMD."
  • LumiThera purchased the AdaptDx Pro and the other MacuLogix assets in July of 2022.
  • The wearable AdaptDx Pro dark adaptometer is the leader in early diagnosis of dry Age-related Macular Degeneration (AMD).
  • Fast Company is a monthly American business magazine published in print and online that focuses on technology, business, and design.

Diopsys, Inc. Announces Move to Expanded Headquarters in New Jersey

Retrieved on: 
Wednesday, June 8, 2022
Severe cognitive impairment, Research, Food, Ageing, CEO, Letter, Disease, AMD, PMA, FDA, Patient, Laboratory, Acquisition, CE marking, Union, Geographic atrophy, Prevalence, PBM, Medical Affairs Bureau, Eye, Medical device, Pharmaceutical industry, USS Valeda (SP-592), EU

SEATTLE, June 8, 2022 /PRNewswire/ --Diopsys, Inc., a leader in modern visual electrophysiology medical devices today announced its move to expanded headquarters in Cedar Knolls, New Jersey.

Key Points: 
  • SEATTLE, June 8, 2022 /PRNewswire/ --Diopsys, Inc., a leader in modern visual electrophysiology medical devices today announced its move to expanded headquarters in Cedar Knolls, New Jersey.
  • LumiThera's acquisition of Diopsys created a complementary diagnosis and monitoring platform for the Valeda Light Delivery System, LumiThera's leading treatment platform.
  • "The new east coast operations center will aid the global expansion of the combined theranostic platforms," indicated Matt Emmer, Vice President, Medical Affairs, Diopsys.
  • LumiThera's recently announced the topline 13-month U.S. LIGHTSITE III trial data in intermediate dry Age-related Macular Degeneration (AMD) patients.

Diopsys, Inc. Announces Move to Expanded Headquarters in New Jersey

Retrieved on: 
Wednesday, June 8, 2022
Severe cognitive impairment, Research, Food, Ageing, CEO, Letter, Disease, AMD, PMA, FDA, Patient, Laboratory, Acquisition, CE marking, Union, Geographic atrophy, Prevalence, PBM, Medical Affairs Bureau, Eye, Medical device, Pharmaceutical industry, USS Valeda (SP-592), EU

SEATTLE, June 8, 2022 /PRNewswire/ --Diopsys, Inc., a leader in modern visual electrophysiology medical devices today announced its move to expanded headquarters in Cedar Knolls, New Jersey.

Key Points: 
  • SEATTLE, June 8, 2022 /PRNewswire/ --Diopsys, Inc., a leader in modern visual electrophysiology medical devices today announced its move to expanded headquarters in Cedar Knolls, New Jersey.
  • LumiThera's acquisition of Diopsys created a complementary diagnosis and monitoring platform for the Valeda Light Delivery System, LumiThera's leading treatment platform.
  • "The new east coast operations center will aid the global expansion of the combined theranostic platforms," indicated Matt Emmer, Vice President, Medical Affairs, Diopsys.
  • LumiThera's recently announced the topline 13-month U.S. LIGHTSITE III trial data in intermediate dry Age-related Macular Degeneration (AMD) patients.